sexta-feira , 24 maio 2024
Capa » International News

International News

Carmot acquisition propels Roche to forefront of obesity drug leadership

Carmot acquisition propels Roche to forefront of obesity drug leadership, finds GlobalData

In a significant move in December 2023, Roche completed the acquisition of the US-based company Carmot Therapeutics in a deal worth $2.9 billion. This strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. This acquisition positions Roche on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others, according to GlobalData, a leading data and analytics company.

GlobalData’s Technology Foresights model recognizes GLP-1 analogues as a high-impact innovation, with accelerating patent trends and other markers indicating their near-term impact. Notably, leaders in this space, like Novo Nordisk and Eli Lilly, have experienced significant success, with share prices surging over 20% in 2023 year on year due to the sales of their respective GLP-1 agonist brands, Wegovy and Mounjaro.

The Technology Foresights model also identifies over 70 companies, including early-stage ventures, actively developing innovative products utilizing GLP-1 analogues. The model further suggests that these molecules, primarily targeting obesity and type 2 diabetes, are also being explored for applications in neurological disorders and NASH type Hepatitis.

Sourabh Nyalkalkar, Practice Head of Innovation Products at GlobalData comments: “As a major player in the pharmaceutical industry, Roche has traditionally focused its research and development (R&D) efforts on cancer research, diagnostics, and gene therapies, as evidenced by the 120+ innovation areas tracked for Roche on the Technology Foresights model. However, innovations in lifestyle disorders, such as GLP-1 analogues, were not a key focus until this recent acquisition.”

PR Chart - GLP1 - Tf.png

On the other hand, Carmot Therapeutics, a privately held company, centred its innovation portfolio almost entirely on GLP-1 agonists. Two out of its four molecules have received positive responses in Phase I clinical trials, positioning Carmot among the leaders in the field of GLP-1 analogue innovation, as identified by GlobalData’s proprietary framework.

Sourabh concludes: “Roche’s well-timed move aligns with the resounding success of GLP-1 agonists like Ozempic, Wegovy, and Mounjaro. The shift in Roche’s position is evident on the innovation leadership map. This move also signals a potential trend, suggesting that other major pharmaceutical players with a strong market presence may be actively seeking targets with robust innovation portfolios in GLP-1 analogues. The Technology Foresights model emerges as a valuable tool for evaluating potential targets in this evolving landscape.”

Clasado Biosciences collaborates with leading scientists to advance prebiotics in medical nutrition field

Clasado Biosciences (‘Clasado’), developer of the proprietary prebiotic ingredient Bimuno GOS, is collaborating with esteemed scientists through a newly established scientific advisory board to further develop the future role of prebiotics within medical nutrition.

This strategic initiative highlights Clasado’s commitment to driving scientific advancements in the health and nutrition industry through microbiome modulation. Notably, this represents a step forward in the exploration and utilisation of prebiotics as part of dietary health interventions.

The collaboration consists of Clasado members Per Rehné (CEO), Dr Frederic Narbel (VP of Sales B2B) and Dr Lucien Harthoorn (R&D Director), and renowned scientific advisors: 

  • Prof Georg Holländer: Professor and Head of the Department of Paediatrics at the University of Oxford (UK), and Director of the Botnar Research Centre for Child Health (Basel, Switzerland). He is an expert in immunology with a keen interest in thymus and T cell biology and has authored over 100 publications in peer-reviewed journals.
  • Prof Matthias Kloor: Deputy Medical Director at the Department of Applied Tumor Biology of the Institute of Pathology at Heidelberg University Hospital (DE), and author of more than 190 publications in peer-reviewed scientific journals. He has also received several scientific honours.
  • Prof Huub Savelkoul: After being Professor in Cell Biology and Immunology from 2000 to 2022 at Wageningen University and Research (NL) he retired in 2023, and has published almost 400 peer-reviewed research papers. He has received several awards for his research and contribution to education.

Clasado is proud to be working with these experts to sharpen the scientific agenda and share valuable insights and experiences to propel the future of prebiotic development and use in medical nutrition and beyond.

A driving force in the biotics field, Clasado Biosciences has long been dedicated to advancing prebiotic research and innovation. With the insight of the scientific advisory board members, the company aims to uncover new possibilities for the application of prebiotics in critical health areas. 

Dr Lucien Harthoorn, R&D Director at Clasado Biosciences, expressed the significance of the collaboration, stating: “The future of prebiotics, specifically galactooligosaccharides and potential novel oligosaccharides holds immense promise in the medical nutrition field – and we are working on uncovering the potential. Clasado’s strategic involvement in this area showcases our commitment to driving prebiotic capabilities forward, and we are honoured to work alongside such esteemed scientific advisors to achieve our shared goals.”

The scientific advisory board follows a submission involving Clasado, which enabled galactooligosaccharides (GOS) to be permitted by the European Commission for use in foods for special medical purposes (FSMPs), further driving the future potential of prebiotics in health and medical applications.

Per Rehné adds: “As we look to the future of medical nutrition, gut microbiome modulation holds great potential and could play a key role in improving human health. Driven by rising global awareness, eyes are on the capabilities of prebiotics, which makes initiatives such as the new scientific advisory board all the more important. For us, this represents an opportunity to better understand where prebiotics can fit into healthcare strategies. Through the power of science and collaboration, we’re aiming to expand the event horizon of the prebiotic category and how it could change areas of application.

“Through our continued research and discussion, we are painting a clearer picture of where prebiotics can support in the day to day management of health, such as gastrointestinal, immune and cognitive health, and we’re excited to be exploring the synergies beyond.”

For further information on Clasado Biosciences and the scientific excellence behind Bimuno GOS, please visit

Amgen olpasiran may fill critical treatment gap in lowering Lp(a), opines GlobalData

Amgen’s olpasiran, a small interfering RNA (siRNA), is making strides in reducing Lp(a) levels significantly in patients with cardiovascular disease. This is noteworthy as elevated Lp(a) is considered a potent risk factor for heart disease and stroke. It also underscores olpasiran’s potential to address a vital treatment gap, representing a pivotal advancement in the realm of dyslipidemia, according to GlobalData, a leading data and analytics company. 

The latest data from the final analysis of the Phase II OCEAN(a)-DOSE study showed that olpasiran reduced Lp(a) levels in patients by 95%. This study, which resulted from the off-treatment extension period, showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a) for nearly a year after their last dose.

Lp(a) is an atherogenic particle and an independent predictor of CV risk. Elevated levels of Lp(a) in the blood are considered a risk factor for CVD, including heart attack and stroke, as it promotes the formation of blood clots and plaque buildup in the arteries. There are a few strategies that have been shown to lower Lp(a) levels, including niacin, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, antisense oligonucleotides, and lifestyle modifications. GlobalData forecasts olpasiran sales to reach $1.05 billion in 2029. 

Dr Shireen Mohammad, Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments:“At present, there are no specific therapies available in the market that target Lp(a) directly. The standard treatments for dyslipidemia, such as statins and other cholesterol-lowering drugs, are not effective in reducing Lp(a) levels. Therefore, there is a high level of unmet need for therapies targeting other lipid particles, particularly the Lp(a) particle.

“Olpasiran is a promising drug treatment for dyslipidemia as it works by preventing the assembly of Lp(a) and therefore the translation of the apo(a) protein, hence reducing Lp(a) in the circulation. Amgen is currently enrolling patients for a Phase III study.” 

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting

Data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines

Leia Mais »

Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery

London, UK, 28th June 2023 / Sciad Newswire / Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.

Busy with networking and collaboration, the event focused on the most important themes for the future of the pharma industry, from manufacturing to drug delivery and sustainability to socioeconomic challenges. A particular highlight was the event’s Gala reception, where visitors enjoyed an awe-inspiring talk by Nicolas Hamilton, British Touring Car Championship Driver, who was given a standing ovation.

Industry change

With attendees from Google, McKinsey, Merck, GSK, Roche, and Johnson & Johnson, speakers highlighted the need to develop systems that account for future needs and create platforms that can be scaled through multiple networks simultaneously. Optimisation and manufacturing speed were key themes, as well as utilising data and AI to improve supply chains.

Elena Bayrak, Pipeline Strategy and Operations at Novartis, appreciated the sector-wide approach to tackling pressing topics:

“I really enjoyed how Connect in Pharma is bringing the pharma industry together with new technologies within packaging, drug delivery systems and such critical topics like diversity and sustainability.”

The ‘Women in Pharma’ panel tackled difficult topics such as inappropriate behaviour in the workplace, emphasising the need for diversity and equality, both for wellbeing and business success.

Global partnerships and data sharing

Over the two-day event, speakers from around the world discussed common issues. Collaboration on a global scale is required to make equitable changes that give the industry longevity. Questions from the audience focused on equity relating to low- and middle-income countries, asking the panel what is needed to facilitate effective sharing of technologies and innovation. Sharing innovation was also raised in the context of IP, calling for open data and increased access to inventions and advances worldwide.

AI and biotechnology

From biotech to connected devices, visitors at Connect in Pharma learned how technologies can empower doctors and healthcare professionals to be more efficient while keeping patients at the heart of healthcare. Futuristic concepts such as harnessing AI in the body, the bio-revolution, the miniverse and the metaverse were raised as important ideas. Promoting healthy lifestyles and wellness that allow people to better manage their health was an important theme in reducing stress on healthcare services.

Berhard Müllinger, Chief Operating Officer at REYSCA, appreciated the range of opinions and opportunities for connection:

“There was a broad selection of speakers. The panels produced lovely discussions and were open to lots of new opinions. There were lots of opportunities to meet new people. Connect in Pharma is a perfect conference for finding suppliers in lots of different industries.”


Exhibitors representing a wide range of companies — including BD Medical, Gerresheimer, and Mettler-Toledo — highlighted innovative products and services designed to advance all areas of the pharma supply chain. With primary packaging solutions, medical device innovations, drug delivery system products, and numerous contract services, software platforms, and association groups on show, the exhibition area had a wide appeal to the pharma community.

Renan Joel, Divisional Managing Director for Packaging at Easyfairs, concluded: “We are thrilled with the success of this year’s event and the feedback we have received. With more than 70% of existing exhibitors pre-booking for next year, we’re excited about the trajectory of the event. This second edition of Connect in Pharma was an enormous success and represents the growing appetite for solutions in pharma, drug delivery and manufacturing, and we’re grateful for the support of the Directorate General for Economic Development, Research and Innovation (DG EDRI). We look forward to welcoming more of you to the event in June 2024.”  

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J), has recently released new data on Tremfya (guselkumab), a monoclonal antibody that targets IL-23 in adults with moderate-to-severe plaque psoriasis (PsO). Tremfya, the first approved IL-23 inhibitor in the US, has potential for various indications and is forecasted to generate $8.6 billion in global sales by 2029, according to GlobalData, a leading data and analytics company.

Leia Mais »

Black participants represented only 3% of cancer clinical trial participants between 2013 and 2022, finds GlobalData

Diversity within pharmaceutical studies continues to be a problem across a wide variety of clinical trial sectors, with industry sponsors and pivotal studies particularly experiencing issues, says GlobalData. When looking specifically at oncology, the leading data and analytics company found that Black participants are severely underrepresented in these studies, only accounting for 3% of the global oncology clinical trial population.

According to GlobalData’s report, ‘Clinical Trials – The Importance of Diversity in Clinical Trials’, Asian participants accounted for more than 10 times that of the Black population, while white participants accounted for more than 19 times.

Mohamed Abukar, Senior Analyst on the Database Team at GlobalData, comments: “Improving Black enrollment in oncology studies is vital so that biological responses to therapies can be fully understood and the most appropriate treatments can be administered. Further, a lack of diversity in clinical trial populations significantly diminishes the quality of data obtained for drug safety and efficacy profiles. If trial participants are representative of the wider disease population, clinical trials can effectively assess the safety and effectiveness of new or existing therapeutics.”


Relative to other therapy areas, oncology has the greatest number of ‘expanded access’ and ‘companionate use’ program trials using experimental therapeutics. It is, therefore, essential that diverse race groups can receive innovative therapies and that therapeutics that are in development are representative of the disease demographic to prevent excess mortality.

Abukar adds: “A diverse clinical trial population allows us to identify discrepancies in responses across population subgroups, ultimately allowing for a better understanding and a more targeted approach in the administration of therapeutics to diverse populations in a real-world setting. Strategies to improve diversity across the pharma industry must be considered where trial populations vastly differ from the disease demographics to ensure that all population subgroups are well represented in clinical research, especially within the field of oncology.”

Advanced biologic drugs and COVID-19 vaccines creating opportunities for packaging providers to supply big pharma companies, says GlobalData

Injectable drugs and their packaging requirements are providing ample opportunities for packaging firms to supply big pharmaceutical companies, given the volume of vaccines, including the latest Omicron boosters required to tackle the COVID-19 pandemic, and the rising number of biologics, says GlobalData, a leading data and analytics company.

GlobalData’s report, ‘Contract Injectable Packaging Trends in the Bio/Pharma Industry’, reveals that there was an increase in approvals of injectable drugs from 2020 to 2021. The FDA and EMA generally approve more injectable drugs developed by large (market cap $10–100 billion) and mega cap (market cap >$100 billion) pharma companies than by smaller companies with market caps below $10 billion. Non-injectable approvals tend to have more small and mid cap sponsors as a proportion. This is because injectables – such as vaccines and monoclonal antibodies – are more complex than oral solid dose drugs – such as tablets – and so tend to be developed by larger companies with deeper pockets.

Adam Bradbury, Pharma Analyst at GlobalData, comments: “For injectable drugs, the FDA’s New Drug Application (NDA) approvals were relatively high in 2021 for small cap and mega cap drug sponsors. The number of approved injectable drugs sponsored by small, large, and mega cap companies increased since 2020.”


Bradbury continues: “The trend of small cap approvals increasing is potentially advantageous to contract manufacturing organisations (CMOs), given that historically their clients are more likely to be smaller companies that are unable to invest in their own facilities or enhance their own capabilities.”

The outsourcing propensity (the percentage of approved drugs for which a pharma sponsor company outsources manufacturing) is influenced greatly by the sponsor’s market cap and ability to acquire capabilities to package rather than outsourcing the task to a contractor. Innovative injectable products are more frequently sponsored by large and mega cap pharma companies than non-injectable or generic approvals.

Bradbury concludes: “Certain innovative products like cell and gene therapies have a limited pool of staff and expertise that can engage with their production; large CMOs have been acquiring these capabilities in recent years and, again, large and mega cap sponsors will require these services.”

SEA Vision and Marchesini Group launch a new blister serialization and aggregation solution at ACHEMA 2022

Pavia, July 14, 2022 – SEA Vision and Marchesini Group are launching a brand-new solution on the market for primary pack serialization and aggregation, comprising a complete range of technologies to print, inspect and pack serialized blisters and perform aggregation with cartons, all integrated in a 4.0 environment.

Leia Mais »

Cold Chain Technologies Announces Regional Manufacturing of CCT Thermal Covers in Montevideo (Uruguay)

FRANKLIN, Mass., June 10, 2022 — Cold Chain Technologies, LLC (“CCT” or “Company”), a leading global provider of thermal packaging solutions for the transportation of temperature-sensitive products for the life sciences industry, announced its further expansion into Latin America with the opening of a new manufacturing facility for the production of CCT Thermal Covers, powered by Tyvek®, in Montevideo (Uruguay).

The new regional manufacturing site, which is expected to start operations by September 2022, will enhance service for customers in the life sciences industry by manufacturing CCT Thermal Covers locally. Latin America is a key growth market for CCT as it continues expansion worldwide. With more than 50 years of ensuring product safety in transit, CCT has built a reputation as the industry’s most innovative and reliable provider to the largest global life sciences companies and distributors.

“By being global and acting local, we ensure that we are providing best-in-class services and products while enhancing our operational capabilities within the Latin American region to support the needs of our clients,” said Vanessa Burri, CCT Regional Sales Director for Latin America.

Kristof De Smedt, Global Business Unit Director for the CCT Thermal Covers Business Unit, stated, “We are extremely proud to further expand our global manufacturing network with a new conversion site in Uruguay in order to provide CCT’s thermal covers throughout the entire Latin American region. CCT Thermal Covers, powered by Tyvek®, are validated in a wide variety of distribution applications worldwide to secure integrity and efficacy of temperature-sensitive healthcare and life science products, including the COVID-19 vaccine.”

× Fale com os gestores